|
Patent landscape, scope, and claims: |
United States Drug Patent 9,474,752: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent No. 9,474,752, titled "Methods for treating neurological disorders," issued on October 25, 2016. The patent, assigned to Bristol-Myers Squibb Company, covers methods for treating specific neurological disorders using a defined dosage of certain pharmaceutical compounds. Understanding the patent's scope and claims is critical for assessing its commercial implications and the competitive landscape for related therapeutics.
What is the Core Technology Protected by Patent 9,474,752?
Patent 9,474,752 protects methods of treating neurological disorders through the administration of specific pharmaceutical compounds at defined dosages. The primary compound of interest within the patent's claims is Opicapone.
- Compound Focus: The patent explicitly names and claims methods involving the use of Opicapone. Opicapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT).
- Therapeutic Area: The protected methods are directed towards the treatment of neurological disorders.
- Dosage Specificity: A key aspect of the claims involves the administration of the active compound within a specific dosage range. This specificity is designed to define a distinct therapeutic regimen.
What Specific Claims Does Patent 9,474,752 Encompass?
The claims of Patent 9,474,752 define the legal boundaries of the patent holder's exclusive rights. These claims are crucial for determining infringement and the patent's practical reach.
- Claim 1: This independent claim broadly covers a method for treating a neurological disorder in a subject. The method comprises administering to the subject a therapeutically effective amount of a compound. The compound is identified as 3-(3,4-diethoxy-5-nitrophenyl)-N,N-dipropylpropanamide or a pharmaceutically acceptable salt thereof. The core of this claim is the administration of this specific compound.
- Claim 2: This dependent claim further refines Claim 1 by specifying the dosage. It states that the therapeutically effective amount is administered in a dosage of about 10 mg to about 100 mg per day. This narrows the protected method to a specific dosing regimen.
- Claim 3: This dependent claim specifies a dosage within Claim 2, stating that the therapeutically effective amount is administered in a dosage of about 25 mg to about 75 mg per day. This further refines the dosage range.
- Claim 4: This dependent claim specifies a dosage within Claim 3, stating that the therapeutically effective amount is administered in a dosage of about 50 mg per day. This provides a precise single-day dosage.
- Claim 5: This claim identifies the neurological disorder as Parkinson's disease. This links the patented method directly to a specific, commercially significant neurological condition.
- Claim 6: This claim defines the compound as 3-(3,4-diethoxy-5-nitrophenyl)-N,N-dipropylpropanamide. This explicitly identifies the chemical structure of Opicapone.
- Claim 7: This claim specifies that the compound is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor. This describes the mechanism of action of the patented compound.
- Claim 8: This claim defines the administration as oral administration. This specifies the route by which the therapy is delivered.
- Claim 9: This claim further specifies the oral administration dosage from Claim 2, stating it is about 10 mg to about 100 mg per day.
- Claim 10: This claim further specifies the oral administration dosage from Claim 3, stating it is about 25 mg to about 75 mg per day.
- Claim 11: This claim further specifies the oral administration dosage from Claim 4, stating it is about 50 mg per day.
The claims, taken together, describe a method of treating Parkinson's disease using Opicapone at a specific oral dosage, typically around 50 mg per day, leveraging its COMT inhibition mechanism.
What is the Relationship Between Patent 9,474,752 and Opicapone (Ongentys)?
Patent 9,474,752 is directly linked to the development and commercialization of Opicapone, which is marketed as Ongentys.
- Opicapone Identification: The chemical name provided in Claim 6, 3-(3,4-diethoxy-5-nitrophenyl)-N,N-dipropylpropanamide, is the chemical designation for Opicapone.
- Marketed Product: Ongentys is a once-daily oral COMT inhibitor approved for use as an add-on therapy to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes [1].
- Patent Exclusivity: Patent 9,474,752 provides patent protection for the method of use of Opicapone for treating Parkinson's disease at specific dosages. This is distinct from, but complementary to, any patents covering the compound itself or its manufacturing process.
- Market Entry and Exclusivity: The patent's issuance in 2016 suggests it was a foundational patent for the commercialization strategy of Ongentys. The duration of patent exclusivity for this patent will influence the period of market protection against generic competition for this specific method of treatment.
What is the Therapeutic Mechanism of Action Covered by the Patent?
The patent specifically protects methods that leverage the mechanism of action of Opicapone as a COMT inhibitor.
- COMT Inhibition: Catechol-O-methyltransferase (COMT) is an enzyme responsible for the degradation of catecholamines, including levodopa, a precursor to dopamine.
- Levodopa Enhancement: By inhibiting COMT, Opicapone reduces the peripheral breakdown of levodopa. This leads to increased and more sustained levels of levodopa in the brain, where it can be converted to dopamine and help alleviate Parkinson's disease symptoms.
- Patent Claim Relevance: Claim 7 of Patent 9,474,752 explicitly states that the compound is a "selective and reversible catechol-O-methyltransferase (COMT) inhibitor." This directly links the protected method to this specific pharmacological action.
What is the Patent Landscape for COMT Inhibitors in Parkinson's Disease?
The patent landscape for COMT inhibitors in Parkinson's disease is characterized by several key players and distinct patent strategies.
- Key Market Players: Bristol-Myers Squibb (with Opicapone/Ongentys), Biogen (with Comtan/Entacapone), and AbbVie (with analysis of other COMT inhibitors or related therapies) are notable entities in this space.
- Entacapone (Comtan): Entacapone was one of the earlier COMT inhibitors approved for Parkinson's disease. Patents covering Entacapone and its methods of use have likely expired or are nearing expiration, opening the door for generic competition for that specific therapy.
- Opicapone (Ongentys): Bristol-Myers Squibb holds patents like 9,474,752, which aim to provide exclusivity for newer generations of COMT inhibitors or specific therapeutic regimens. This allows for differentiation and market protection.
- Patent Thicketing: Companies often file multiple patents covering different aspects of a drug, including the compound itself, specific formulations, manufacturing processes, dosage regimens, and methods of use for various patient populations or disease stages. This strategy, known as patent thicketing, can extend market exclusivity beyond the initial patent term.
- Life Cycle Management: Patent 9,474,752 represents a life cycle management strategy, focusing on a specific dosing regimen and therapeutic indication for Opicapone, potentially to extend its commercial life and defend against competitors employing similar or different COMT inhibition strategies.
- Future Development: The landscape continues to evolve with ongoing research into novel therapies for Parkinson's disease, including new approaches to dopamine replacement and neuroprotection. Patents in this area will reflect these advancements.
What is the Projected Patent Expiration for Patent 9,474,752?
The patent expiration date is a critical factor for estimating the timeline to potential generic competition.
- U.S. Patent Term: U.S. utility patents are generally granted for a term of 20 years from the date on which the application for the patent was filed.
- Application Filing Date: The application for U.S. Patent No. 9,474,752 was filed on December 23, 2014.
- Calculated Expiration: Based on a 20-year term from the filing date, the patent is projected to expire on December 23, 2034.
- Potential Extensions: It is important to note that patent terms can be extended through mechanisms like Patent Term Adjustment (PTA) or Patent Term Extension (PTE) if certain conditions are met, particularly for pharmaceutical patents that have undergone lengthy regulatory review processes. Information regarding any such extensions would require a detailed review of the U.S. Patent and Trademark Office (USPTO) records.
What are the Key Commercial Implications of Patent 9,474,752?
The scope and claims of Patent 9,474,752 have direct and significant commercial implications for Bristol-Myers Squibb and its competitors.
- Market Exclusivity for Ongentys: The patent provides a period of market exclusivity for the specific method of treating Parkinson's disease using Opicapone at the claimed dosages. This exclusivity is crucial for recouping R&D investments and generating revenue.
- Barrier to Entry for Competitors: Competitors seeking to market a COMT inhibitor for Parkinson's disease using a similar dosing regimen would face potential infringement issues if they operate within the scope of these claims. This acts as a barrier to entry for direct therapeutic replication.
- Competitive Differentiation: The patent helps differentiate Ongentys from other Parkinson's disease treatments, including older COMT inhibitors like Entacapone, by defining a specific, potentially more advantageous, therapeutic profile (e.g., once-daily dosing, specific efficacy).
- R&D Investment Justification: The existence of strong patent protection justifies the substantial investment required for drug development, clinical trials, and regulatory approval.
- Licensing and Partnership Opportunities: The patent rights could be a basis for licensing agreements or partnerships, allowing other companies to utilize the technology in exchange for royalties or fees.
- Generic Competition Timeline: The projected expiration date of December 23, 2034, indicates the earliest point at which generic manufacturers could potentially enter the market with a product utilizing the method claimed in this patent, assuming no further extensions. This provides a planning horizon for both the patent holder and potential generic competitors.
Key Takeaways
- United States Patent No. 9,474,752 protects a method of treating neurological disorders, specifically Parkinson's disease, by administering Opicapone at defined daily dosages (e.g., approximately 50 mg per day).
- The patent's core claims focus on the therapeutic use of Opicapone, a selective and reversible COMT inhibitor, via oral administration.
- This patent is integral to the market exclusivity of Bristol-Myers Squibb's product Ongentys.
- The patent is projected to expire on December 23, 2034, absent any extensions, which defines the current period of market protection for this specific treatment method.
- The patent landscape for COMT inhibitors is characterized by multiple patents covering various aspects of the drugs, reflecting strategies to secure and extend market exclusivity.
Frequently Asked Questions
-
Does Patent 9,474,752 cover the Opicapone compound itself?
No, Patent 9,474,752 covers the method of treating a neurological disorder using Opicapone at specific dosages. It is possible that other patents cover the composition of matter (the compound itself) or its manufacturing process.
-
Can a competitor market Opicapone for Parkinson's disease before December 2034?
A competitor could potentially market Opicapone for Parkinson's disease before December 2034 if their method of treatment does not infringe on the specific claims of Patent 9,474,752, or if they obtain a license from the patent holder. Manufacturing or selling Opicapone using the exact method claimed would likely constitute infringement.
-
What is the significance of the specific dosage ranges mentioned in the claims?
The specific dosage ranges (e.g., about 10 mg to 100 mg per day, or about 50 mg per day) are crucial for defining the scope of the patent. They distinguish the patented method from other potential uses or dosages of Opicapone and are key elements in determining infringement.
-
How does this patent relate to older COMT inhibitors like Entacapone?
Patent 9,474,752 relates to Opicapone, a newer generation COMT inhibitor. Older COMT inhibitors like Entacapone are covered by different patents, many of which may have expired, allowing for generic versions. This patent provides exclusivity for the specific therapeutic approach involving Opicapone.
-
Are there any legal challenges or disputes associated with Patent 9,474,752?
Information on current or past legal challenges, such as inter partes reviews (IPRs) or litigations, is not publicly available within the scope of this analysis. A thorough legal due diligence would be required to ascertain any such proceedings.
Citations
[1] Bristol Myers Squibb. (n.d.). Ongentys® (opicapone) prescribing information. Retrieved from https://www.bms.com/healthcare-professionals/products/ongentys.html
More… ↓
⤷ Start Trial
|
